Research programme: obesity therapy - Halsa PharmaceuticalsAlternative Names: ZAG; Zinc-α2-glycoprotein
Latest Information Update: 02 Nov 2009
At a glance
- Originator Halsa Pharmaceuticals
- Class Recombinant proteins
- Mechanism of Action Glycoprotein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Obesity